Neuropro Therapeutics, Inc.

This study tests whether an experimental drug called NPT 2042 can reduce the number and length of absence seizures (brief staring spells) in people aged 16-75 with genetic generalized epilepsy. Each participant will receive both the drug and a placebo in random order, with a two-…